182 related articles for article (PubMed ID: 21857357)
1. Comparative effectiveness of initial antiretroviral therapy regimens: ACTG 5095 and 5142 clinical trials relative to ART-CC cohort study.
Mugavero MJ; May M; Ribaudo HJ; Gulick RM; Riddler SA; Haubrich R; Napravnik S; Abgrall S; Phillips A; Harris R; Gill MJ; de Wolf F; Hogg R; Günthard HF; Chêne G; D'Arminio Monforte A; Guest JL; Smith C; Murillas J; Berenguer J; Wyen C; Domingo P; Kitahata MM; Sterne JA; Saag MS; ; ; ;
J Acquir Immune Defic Syndr; 2011 Nov; 58(3):253-60. PubMed ID: 21857357
[TBL] [Abstract][Full Text] [Related]
2. Efavirenz-based simplification after successful early lopinavir-boosted-ritonavir-based therapy in HIV-infected children in Burkina Faso and Côte d'Ivoire: the MONOD ANRS 12206 non-inferiority randomised trial.
Dahourou DL; Amorissani-Folquet M; Malateste K; Amani-Bosse C; Coulibaly M; Seguin-Devaux C; Toni T; Ouédraogo R; Blanche S; Yonaba C; Eboua F; Lepage P; Avit D; Ouédraogo S; Van de Perre P; N'Gbeche S; Kalmogho A; Salamon R; Meda N; Timité-Konan M; Leroy V;
BMC Med; 2017 Apr; 15(1):85. PubMed ID: 28434406
[TBL] [Abstract][Full Text] [Related]
3. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial.
Gulick RM; Ribaudo HJ; Shikuma CM; Lalama C; Schackman BR; Meyer WA; Acosta EP; Schouten J; Squires KE; Pilcher CD; Murphy RL; Koletar SL; Carlson M; Reichman RC; Bastow B; Klingman KL; Kuritzkes DR;
JAMA; 2006 Aug; 296(7):769-81. PubMed ID: 16905783
[TBL] [Abstract][Full Text] [Related]
4. Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.
Sturt AS; Dokubo EK; Sint TT
Cochrane Database Syst Rev; 2010 Mar; (3):CD008440. PubMed ID: 20238370
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness analysis of tenofovir/emtricitabine and abacavir/lamivudine in combination with efavirenz or atazanavir/ritonavir for treatment-naïve adults with HIV-1 infection in the UK, based on the AIDS Clinical Trials Group 5202 clinical trial.
Wilkins E; Fisher M; Brogan AJ; Talbird SE; La EM
HIV Med; 2016 Aug; 17(7):505-15. PubMed ID: 26663715
[TBL] [Abstract][Full Text] [Related]
6. Abacavir/lamivudine versus tenofovir DF/emtricitabine as part of combination regimens for initial treatment of HIV: final results.
Sax PE; Tierney C; Collier AC; Daar ES; Mollan K; Budhathoki C; Godfrey C; Jahed NC; Myers L; Katzenstein D; Farajallah A; Rooney JF; Ha B; Woodward WC; Feinberg J; Tashima K; Murphy RL; Fischl MA;
J Infect Dis; 2011 Oct; 204(8):1191-201. PubMed ID: 21917892
[TBL] [Abstract][Full Text] [Related]
7. Prospective, randomized, open label trial of Efavirenz vs Lopinavir/Ritonavir in HIV+ treatment-naive subjects with CD4+<200 cell/mm3 in Mexico.
Sierra-Madero J; Villasis-Keever A; Méndez P; Mosqueda-Gómez JL; Torres-Escobar I; Gutiérrez-Escolano F; Juárez-Kasusky I; Magana-Aquino M; Ramos-Santos C; Pérez-Saleme L; Rangel-Frausto S; Antuna-Puente B; Soto-Ramírez LE; Lima V; Belaunzarán-Zamudio F; Crabtree-Ramírez B; Montaner J
J Acquir Immune Defic Syndr; 2010 Apr; 53(5):582-8. PubMed ID: 20090545
[TBL] [Abstract][Full Text] [Related]
8. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
; Mugavero MJ; May M; Harris R; Saag MS; Costagliola D; Egger M; Phillips A; Günthard HF; Dabis F; Hogg R; de Wolf F; Fatkenheuer G; Gill MJ; Justice A; D'Arminio Monforte A; Lampe F; Miró JM; Staszewski S; Sterne JA
AIDS; 2008 Nov; 22(18):2481-92. PubMed ID: 19005271
[TBL] [Abstract][Full Text] [Related]
9. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
[TBL] [Abstract][Full Text] [Related]
10. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
11. Poor early virologic performance and durability of abacavir-based first-line regimens for HIV-infected children.
Technau KG; Lazarus E; Kuhn L; Abrams EJ; Sorour G; Strehlau R; Reubenson G; Davies MA; Coovadia A
Pediatr Infect Dis J; 2013 Aug; 32(8):851-5. PubMed ID: 23860481
[TBL] [Abstract][Full Text] [Related]
12. First-line highly active antiretroviral regimens in 2001-2002 in the French Hospital Database on HIV: combination prescribed and biological outcomes.
Potard V; Rey D; Mokhtari S; Frixon-Marin V; Pradier C; Rozenbaum W; Brun-Vezinet F; Costagliola D;
Antivir Ther; 2007; 12(3):317-24. PubMed ID: 17591021
[TBL] [Abstract][Full Text] [Related]
13. Randomized open-label trial of two simplified, class-sparing regimens following a first suppressive three or four-drug regimen.
Fischl MA; Collier AC; Mukherjee AL; Feinberg JE; Demeter LM; Tebas P; Giuliano M; Dehlinger M; Garren K; Brizz B; Bassett R
AIDS; 2007 Jan; 21(3):325-33. PubMed ID: 17255739
[TBL] [Abstract][Full Text] [Related]
14. Racial differences in virologic failure associated with adherence and quality of life on efavirenz-containing regimens for initial HIV therapy: results of ACTG A5095.
Schackman BR; Ribaudo HJ; Krambrink A; Hughes V; Kuritzkes DR; Gulick RM
J Acquir Immune Defic Syndr; 2007 Dec; 46(5):547-54. PubMed ID: 18193496
[TBL] [Abstract][Full Text] [Related]
15. Association of efavirenz hypersusceptibility with virologic response in ACTG 368, a randomized trial of abacavir (ABC) in combination with efavirenz (EFV) and indinavir (IDV) in HIV-infected subjects with prior nucleoside analog experience.
Demeter LM; DeGruttola V; Lustgarten S; Bettendorf D; Fischl M; Eshleman S; Spreen W; Nguyen BY; Koval CE; Eron JJ; Hammer S; Squires K
HIV Clin Trials; 2008; 9(1):11-25. PubMed ID: 18215978
[TBL] [Abstract][Full Text] [Related]
16. Prevalence and predictive value of intermittent viremia with combination hiv therapy.
Havlir DV; Bassett R; Levitan D; Gilbert P; Tebas P; Collier AC; Hirsch MS; Ignacio C; Condra J; Günthard HF; Richman DD; Wong JK
JAMA; 2001 Jul; 286(2):171-9. PubMed ID: 11448280
[TBL] [Abstract][Full Text] [Related]
17. Comparative effectiveness of efavirenz, protease inhibitors, and raltegravir-based regimens as first-line treatment for HIV-infected adults: a mixed treatment comparison.
Vieira MC; Kumar RN; Jansen JP
HIV Clin Trials; 2011; 12(4):175-89. PubMed ID: 22044854
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment.
Smith KY; Patel P; Fine D; Bellos N; Sloan L; Lackey P; Kumar PN; Sutherland-Phillips DH; Vavro C; Yau L; Wannamaker P; Shaefer MS;
AIDS; 2009 Jul; 23(12):1547-56. PubMed ID: 19542866
[TBL] [Abstract][Full Text] [Related]
19. Peripheral and central fat changes in subjects randomized to abacavir-lamivudine or tenofovir-emtricitabine with atazanavir-ritonavir or efavirenz: ACTG Study A5224s.
McComsey GA; Kitch D; Sax PE; Tebas P; Tierney C; Jahed NC; Myers L; Melbourne K; Ha B; Daar ES
Clin Infect Dis; 2011 Jul; 53(2):185-96. PubMed ID: 21690627
[TBL] [Abstract][Full Text] [Related]
20. Virologic response in children treated with abacavir-compared with stavudine-based antiretroviral treatment: a South African multi-cohort analysis.
Technau KG; Schomaker M; Kuhn L; Moultrie H; Coovadia A; Eley B; Rabie H; Wood R; Cox V; Vizcaya LS; Muchiri E; Davies MA;
Pediatr Infect Dis J; 2014 Jun; 33(6):617-22. PubMed ID: 24378944
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
